VB Spine’s Augmented Reality Bet in the Spine Market

M&A activity is off to a strong start in 2026. While several large transactions are drawing attention, we are focusing on a move that could carry long-term implications for the spine market: VB Spine’s agreement to acquire the rights to the xvision Spine System from Augmedics.

This is not a routine tuck-in acquisition. It reflects a deliberate strategy aimed at addressing structural challenges that have historically limited growth in spine.

Before looking at the data, a quick refresher on the two companies involved.

A Newly Formed Leader Meets AR Pioneer

VB Spine is currently the largest privately held spine company, despite being less than one year old (at the time of this article’s publication). The company was formed in April 2025 when the Viscogliosi Brothers acquired Stryker’s U.S. spinal implants business, excluding MAKO and Copilot. That transaction immediately created a major player with a broad portfolio, expanding global distribution, and a surgeon-focused approach.

Augmedics built its business around augmented reality in the operating room. Its core concept is straightforward: allow surgeons to visualize anatomy in 3D without diverting their attention away from the operative field. The company’s lead product, the xvision Spine System, has been used in more than 10,000 patient cases across the United States.

VB Spine has entered into a definitive agreement to acquire the rights to the xvision Spine System.

Now, let’s examine the broader context.

The Spine Market Growth Profile

The global spine market is valued at approximately $12 billion. Growth, however, has lagged behind other orthopedic segments. From 2025 through 2030, spine device sales are projected to grow at a 3.9% CAGR. Over the same period, joint replacement implants are expected to grow at 4.3% CAGR, and the broader orthopedics market at 4.2% CAGR.

Several dynamics explain the slower trajectory.

Spine procedures are highly complex, and outcomes can vary based on surgeon technique. Reimbursement pressure remains a constraint, particularly in high-volume procedures such as lumbar fusion. In addition, spine has been slower than other orthopedic specialties to transition into outpatient settings.

Against that backdrop, VB Spine’s move is notable. Rather than acquiring in a faster-growing niche, the company is investing in a platform that directly targets long-standing friction points.

Addressing Surgeon, Facility, and Patient Needs

Spinal anatomy is highly variable, and the margin for error is small. The xvision Spine System is designed to improve visualization and navigation during surgery.

For surgeons, the system projects real-time 3D guidance directly into the operative field. Optical tracking shows instrument position relative to anatomy without requiring the surgeon to look away at a separate monitor. Its CT-Fluoro registration enables navigation using preoperative CT scans and standard 2D C-arm fluoroscopy, significantly reducing intraoperative radiation exposure for both the surgical team and the patient.

The facility impact is equally important. More than half of U.S. hospitals do not have access to 3D intraoperative imaging systems that many complex spine cases have traditionally required. This creates both cost and utilization barriers. By allowing navigation with equipment already available in most hospitals and ASCs, xvision expands access to advanced guidance capabilities.

Patients are the ultimate beneficiaries. In addition to reduced radiation exposure, accurate device placement is critical in spine procedures. Pedicle screw misplacement is among the most serious technical errors and can result in permanent neurological damage. Multiple clinical studies have reported 97–100% pedicle screw placement accuracy using xvision.

The clinical data, combined with broader facility access, positions the technology as a potential driver of adoption and loyalty.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/vb-spines-augmented-reality-bet-in-the-spine-market 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more